KCC009 |
Katalog-Nr.GC64531 |
KCC009, ein Transglutaminase 2 (TG2)-Inhibitor, induziert eine p53-unabhÄngige Radiosensibilisierung.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 744198-19-4
Sample solution is provided at 25 µL, 10mM.
KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1].
[1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048.
[2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *